Overall objective
NMIBC
Currently, the drug for chemotherapeutic instillation after TURBT in patients with intermediate-risk low grade NMIBC is selected based on doctors’- and institutional preferences. Most frequently, Epirubicin or MMC are used. Currently, no comparative studies focus on this patient population between the different drugs and the selection is not based on biological characteristics.We aim to establish a workflow into the clinical routine, that allows a specific selection of the instilled drug based on molecular characteristics of the respective NMIBC.The current study will test the use of drug screens in PDO for the prediction of treatment in patients. Therefore, we will test the implementation of drug screen in PDO in the workflow of the daily routine.